Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip De Vos

Showing results (101-110 of 125) with videos related to

Pageof 13
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|December 8, 2005
(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation studyBieke Lambert, Klaus Bacher, Luc Defreyne, et al.
Radiation Oncology (London, England)|June 1, 2019
Technical feasibility of [<sup>18</sup>F]FET and [<sup>18</sup>F]FAZA PET guided radiotherapy in a F98 glioblastoma rat modelJeroen Verhoeven, Julie Bolcaen, Valerie De Meulenaere, et al.
Acta Neurologica Belgica|October 29, 2002
Semiquantification of the peripheral-type benzodiazepine ligand [11C]PK11195 in normal human brain and application in multiple sclerosis patientsJan C Debruyne, Koen J Van Laere, Jan Versijpt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 8, 2003
In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damageKatia Vandenbulcke, Filip De Vos, Fritz Offner, et al.
The Oncologist|June 1, 2023
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung CancerMelinda A Pruis, Matthew G Krebs, Ruth Plummer, et al.
Scientific Reports|March 1, 2019
New fluoroethyl phenylalanine analogues as potential LAT1-targeting PET tracers for glioblastomaJeroen Verhoeven, Fabian Hulpia, Ken Kersemans, et al.
Investigational New Drugs|July 31, 2019
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myelomaW Larry Gluck, Mrinal M Gounder, Richard Frank, et al.
Diagnostics (Basel, Switzerland)|October 18, 2017
Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer PatientsWouter Huysse, Frédéric Lecouvet, Paolo Castellucci, et al.
BJU International|June 25, 2017
Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapyAurélie De Bruycker, Bieke Lambert, Tom Claeys, et al.
Plos One|March 4, 2014
Absence of cardiovascular manifestations in a haploinsufficient Tgfbr1 mouse modelMarjolijn Renard, Bram Trachet, Christophe Casteleyn, et al.
Pageof 13

Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
European Journal of Nuclear Medicine and Molecular Imaging|December 8, 2005
(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation studyBieke Lambert, Klaus Bacher, Luc Defreyne, et al.
Radiation Oncology (London, England)|June 1, 2019
Technical feasibility of [<sup>18</sup>F]FET and [<sup>18</sup>F]FAZA PET guided radiotherapy in a F98 glioblastoma rat modelJeroen Verhoeven, Julie Bolcaen, Valerie De Meulenaere, et al.
Acta Neurologica Belgica|October 29, 2002
Semiquantification of the peripheral-type benzodiazepine ligand [11C]PK11195 in normal human brain and application in multiple sclerosis patientsJan C Debruyne, Koen J Van Laere, Jan Versijpt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 8, 2003
In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damageKatia Vandenbulcke, Filip De Vos, Fritz Offner, et al.
The Oncologist|June 1, 2023
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung CancerMelinda A Pruis, Matthew G Krebs, Ruth Plummer, et al.
Scientific Reports|March 1, 2019
New fluoroethyl phenylalanine analogues as potential LAT1-targeting PET tracers for glioblastomaJeroen Verhoeven, Fabian Hulpia, Ken Kersemans, et al.
Investigational New Drugs|July 31, 2019
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myelomaW Larry Gluck, Mrinal M Gounder, Richard Frank, et al.
Diagnostics (Basel, Switzerland)|October 18, 2017
Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer PatientsWouter Huysse, Frédéric Lecouvet, Paolo Castellucci, et al.
BJU International|June 25, 2017
Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapyAurélie De Bruycker, Bieke Lambert, Tom Claeys, et al.
Plos One|March 4, 2014
Absence of cardiovascular manifestations in a haploinsufficient Tgfbr1 mouse modelMarjolijn Renard, Bram Trachet, Christophe Casteleyn, et al.
Pageof 13